<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818479</url>
  </required_header>
  <id_info>
    <org_study_id>HCI61077</org_study_id>
    <nct_id>NCT01818479</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies</brief_title>
  <official_title>Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, dose finding trial to assess the efficacy of Treg/Tcon addback to partially
      matched related donor stem cells. The maximum tolerated dose will be established using 3
      subjects per dose level, with an expansion cohort at the maximum tolerated dose.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial discontinued prior to starting Phase II portion due to low accrual.
  </why_stopped>
  <start_date type="Actual">July 12, 2013</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of acute GVHD</measure>
    <time_frame>36 months</time_frame>
    <description>Rate of acute Graft Versus Host Disease (GVHD) grade III-IV at Day +100 post transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Engraftment</measure>
    <time_frame>36 months</time_frame>
    <description>Day +28 and +100 neutrophil engraftment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at Day 100</measure>
    <time_frame>36 months</time_frame>
    <description>Day +100 and one year survival Day +100 and one year transplant related mortality Day +100 and one year relapse rates</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>High Risk Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>stem cell transplant</intervention_name>
    <description>Open label, dose finding trial with two treatment regimens, Busulfan and Total Body Irradiation (TBI) with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.</description>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell transplant</intervention_name>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Age 0-70 years 2. Karnofsky or Lansky Performance status &gt;70% 3. High risk hematologic
        malignancy 4. Acute myeloid leukemia (AML) with one or more of the following criteria:
        4a.Poor risk cytogenetics, including -5, 5q-, -7, 7q-, t(9;22); complex cytogenetics (&gt;3
        abnormalities); or normal cytogenetics with Flt3 internal tandem duplication (ITD), in
        first or subsequent complete remission (CR).

        4b. Relapsed or primary refractory AML with &lt;10% blasts in the peripheral blood.

        4c. Subjects in first complete remission (CR1) who required two cycles of induction to
        achieve remission may be included at the discretion of the treating physician.

        4d. Standard risk or intermediate risk cytogenetics in second or subsequent CR (enrolled at
        the discretion of the treating physician).

        5. Acute lymphoblastic leukemia (ALL) with one of the following criteria: 5a. Second or
        subsequent CR 5b. Any partial remission (PR) (no circulating blasts) 5c. High-risk ALL in
        first CR including (Ph+, t(4:11), complex karyotype, hypodiploidy (&lt;44 chromosomes), or
        positive minimal residual disease (MRD) after induction 6. Myelodysplasia, intermediate -2
        (score 1.5-2.0) or high risk (score &gt;2.5) by the International Prognostic Score System.

        7. Myeloproliferative Disorders (include chronic myelomonocytic leukemia (CMML), agnogenic
        myeloid metaplasia (AMM) or Idiopathic Myelofibrosis, and JMML) with excess blasts (&gt;5%) 8.
        Chronic myeloid leukemia (CML) with one of the following criteria: 8a. Second or subsequent
        chronic phase 8b. Accelerated phase 8c. blast crisis 9. Non-Hodgkin's lymphoma (NHL)
        meeting one of the following criteria: 9a. Relapse after autologous stem cell
        transplantation with evidence of responsive disease.

        9b. Subject with chemosensitive relapse who have no option for autologous stem cell
        transplantation due to blood or marrow involvement or failure to mobilize autologous stem
        cells or are not considered eligible for autologous transplant by their treating physician.

        9c. Hodgkin's Lymphoma: relapse after autologous hematopoietic cell transplantation (HCT),
        chemo-refractory disease 9d. Multiple myeloma: per National Comprehensive Cancer Network
        (NCCN) guidelines. Updated annually at: www.nccn.org 10. No suitable human leukocyte
        antigen (HLA)-identical sibling donor. 11. No identified 8/8 (based upon A, B, C, DR beta 1
        (DRB1) loci) allele matched unrelated donor, or unable to wait sufficient time to procure a
        8/8 allele matched unrelated donor 12. Available HLA 3-5/6 matched genotypically
        haploidentical partially matched related donor 13. Female subjects must be surgically
        sterile, postmenopausal (minimum 1 year without menses), or agree to use approved form of
        contraception from the time of signing the informed consent form through Day +100. Male
        subjects must also agree to use an approved form of birth control for either themselves or
        their partner, as appropriate, from the time of signing the informed consent form through
        Day +100.

        14. Able to provide informed consent and have signed an approved consent form that conforms
        to federal and institutional guidelines.

        Exclusion Criteria:

          1. Available HLA identical matched sibling donor (unless having failed a prior allogeneic
             transplant from an HLA identical matched sibling)

          2. Recipient HLA antibodies against donor HLA

          3. Any of the following organ dysfunctions:

               1. Cardiac- left ventricular ejection fraction &lt;40%, symptomatic coronary artery
                  disease, or uncontrolled arrhythmias

               2. Pulmonary- forced expiratory volume at one second (FEV1) or diffusion capacity of
                  lung for carbon monoxide (DLco)&lt;40% or need for use of supplemental oxygen

               3. Renal- calculated or measured glomerular filtration rate (GFR) &lt;30 ml/min,
                  dialysis requirement, or prior renal transplant

               4. Hepatic- bilirubin &gt; 2.0, alanine aminotransferase (ALT) &gt; 2.5 X upper limit of
                  normal (ULN), cirrhosis

          4. Subjects with active or uncontrolled bacterial, viral, or fungal infections requiring
             systemic therapy.

          5. Subjects who have tested positive for HIV.

          6. Pregnant women, nursing mothers or women of child-bearing potential who are unwilling
             to use medically accepted methods of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Boyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huntsman Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

